EncephalX key facts
as of Oct 2026- Developer of cranial implants designed to reduce the risk of complications for patients treated for head trauma, stroke, or subdural hematoma.
- EncephalX is valued at approximately $9.6M as of Oct 2026 (last reported valuation).
- It has raised $2.7M; the latest was Seed Round ($2.3M) in Feb 2026.
- Notable investors include Investissement Quebec, Front Row Ventures, Angels Capital, ACET, Anges Québec — 9 tracked in total.
- Status: Privately Held (backing).
EncephalX's last reported valuation, Feb 2026. Nothing priced has surfaced since.
- ·Watch EncephalX: the Monday email on marks, rounds and moves
EncephalX funding rounds
No funding rounds for EncephalX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
EncephalX valuation
EncephalX's last reported valuation was $9.6 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.
EncephalX investors
9 investors are on record for EncephalX, including Investissement Quebec, Front Row Ventures, Angels Capital and ACET.
About EncephalX
Developer of cranial implants designed to reduce the risk of complications for patients treated for head trauma, stroke, or subdural hematoma. The company's platform offers a variety of features, including a dynamic cranioplasty system that allows the skull to expand as the brain heals, reducing the need for additional surgery, enabling neurosurgeons to provide patients with a quality of life and reduce the overall cost of care.
- Sector
- Healthcare
- HQ
- Sherbrooke, Canada
- Founded
- 2020
- Employees
- 5
- Website
- encephalx.ca/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.